跳至主要内容
临床试验/NCT07718815
NCT07718815招募中不适用

HLA B Leader in Patients With Psoriatic Arthritis

Centre Hospitalier Universitaire, Amiens1 个研究点 分布在 1 个国家目标入组 658 人开始时间: 2025年5月6日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
658
试验地点
1
主要终点
prevalence of HLA B leader in both groups

研究概览

简要总结

Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule.

Given this association, these diseases are classically regarded as disorders of adaptive immunity.

In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • For the "Patient" group:
  • Patient over 18 years of age
  • Patient affiliated to a social security scheme
  • Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie.
  • For the "control" group:
  • Individuals over 18 years of age
  • Individual affiliated to a social security scheme
  • Individual having agreed to participate in the study
  • Individuals with no inflammatory or autoimmune diseases

排除标准

  • Patient or control not understanding French
  • Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort.
  • Patient or control objecting to participation in the study

结局指标

主要结局

prevalence of HLA B leader in both groups

时间窗: 1 year

prevalence of HLA B leader in patients with psoriatic rheumatism compared to the healthy group by autoimmune disease

次要结局

  • Prevalence of HLAB27 gene in both groups(1 year)
  • prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism patient group(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验